Portfolio Companies

Sort By:

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

×
Oncology | Clinical | Active

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Visit Site

Developing novel therapies for patients with rare bone and connective tissue disorders.

×
Rare Disease | Clinical | Active

Developing novel therapies for patients with rare bone and connective tissue disorders.

Visit Site

Developing a proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.

×
Rare Disease | Preclinical |

Developing a proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.

Visit Site

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

Public-NSDQ:CARM
×
Oncology | Clinical | Public

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

Visit Site
×

Developing treatments derived from proprietary discovery platform for CNS disorders and neurodegenerative diseases.

×
Neurology | Clinical | Active

Developing treatments derived from proprietary discovery platform for CNS disorders and neurodegenerative diseases.

Visit Site

Cyrus solves difficult protein engineering and structure prediction problems using the most scientifically advanced, powerful, and laboratory-proven software.

×
Rare Disease, Immunology | Preclinical |

Cyrus solves difficult protein engineering and structure prediction problems using the most scientifically advanced, powerful, and laboratory-proven software.

Visit Site

Developing innovative medicines in immunology. Went public in 2021 and was formerly NASDAQ:DICE.

M&A - $2.4B in 2023
×
Oncology, Immunology | Clinical | M&A
M&A - $2.4B in 2023

Developing innovative medicines in immunology. Went public in 2021 and was formerly NASDAQ:DICE.

Visit Site

Harnessing the immune system for improved patient outcomes using a targeted approach.

×
Oncology, Immunology | Clinical | Active

Harnessing the immune system for improved patient outcomes using a targeted approach.

Visit Site
×

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

Public-NSDQ:TRDA
×
Rare Disease | Preclinical | Public

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

Visit Site

Drugging transcription factor complexes through novel pockets, or ‘switch sites’, for cancer.

×
Oncology | Preclinical | Active

Drugging transcription factor complexes through novel pockets, or ‘switch sites’, for cancer.

Visit Site

Minimal residual disease testing platform.

×
Oncology | Commercial | Active

Minimal residual disease testing platform.

Visit Site

Pioneering the most comprehensive multiomics platform for early cancer detection.

×
Oncology | Clinical | Active

Pioneering the most comprehensive multiomics platform for early cancer detection.

Visit Site
×

Broadly applicable biologics platform across  many different therapeutic areas.

×
Rare Disease, Oncology, Immunology | Preclinical | Active

Broadly applicable biologics platform across  many different therapeutic areas.

Visit Site

Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

×
Oncology | Clinical | Active

Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

Visit Site

Developing targeted therapeutics for complex diseases using novel single cell analyses.

×
Oncology, Immunology | Preclinical | Active

Developing targeted therapeutics for complex diseases using novel single cell analyses.

Visit Site

Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

×
Oncology | Preclinical | Active

Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

Visit Site
×

Preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems.

×
Rare Disease, Immunology | Preclinical |

Preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems.

Visit Site

Discovering breakthrough gene editing systems for curing disease.

Public-NSDQ:MGX
×
Rare Disease, Oncology, Immunology | Preclinical | Public

Discovering breakthrough gene editing systems for curing disease.

Visit Site

circRNA platform company for next-generation therapies and vaccines.

×
Rare Disease, Oncology, Immunology | Preclinical | Active

circRNA platform company for next-generation therapies and vaccines.

Visit Site

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

×
Oncology | Clinical | Active

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

Visit Site
×

Developing gene therapies for rare immunology disorders. Went public in 2018 and was formerly NASDAQ:ORTX.

M&A - $0.5B in 2024
×
Rare Disease, Neurology, Immunology | Commercial | M&A
M&A - $0.5B in 2024

Developing gene therapies for rare immunology disorders. Went public in 2018 and was formerly NASDAQ:ORTX.

Visit Site

Developing therapeutics for rare dermatological disorders.

×
Rare Disease, Immunology | Clinical | Active

Developing therapeutics for rare dermatological disorders.

Visit Site

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

Public-NSDQ:PLRX
×
Rare Disease | Clinical | Public

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

Visit Site

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

Public-NSDQ:DTIL
×
Rare Disease, Oncology | Clinical | Public

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

Visit Site
×

Synthetic biology and manufacturing company developing next-generation solutions for new therapeutics and vaccines.

×
Manufacturing | Commercial | Active

Synthetic biology and manufacturing company developing next-generation solutions for new therapeutics and vaccines.

Visit Site

Charting a course to therapeutics for difficult-to-treat cancers.

Public-NSDQ:PYXS
×
Oncology | Preclinical | Public

Charting a course to therapeutics for difficult-to-treat cancers.

Visit Site

Developing targeted biotherapeutics that rebalance the immune system.

×
Immunology | Clinical | Active

Developing targeted biotherapeutics that rebalance the immune system.

Visit Site

Small molecule platform company for alternative modulation of RNA.

×
Rare Disease, Oncology, Neurology | Preclinical | Active

Small molecule platform company for alternative modulation of RNA.

Visit Site
×

Innovation engine for novel antibody therapies

×
Rare Disease, Immunology | Clinical | Active

Innovation engine for novel antibody therapies

Visit Site

Applying an all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale.

×
| |

Applying an all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale.

Visit Site

Overcoming current limitations of CAR-T cell therapeutics by using combining cell and gene editing technologies that address unmet patient need.

×
Oncology | Preclinical | Active

Overcoming current limitations of CAR-T cell therapeutics by using combining cell and gene editing technologies that address unmet patient need.

Visit Site

Bringing best-in-class immune-based therapies to patients in need.

×
Immunology | Clinical | Active

Bringing best-in-class immune-based therapies to patients in need.

Visit Site
×